Clinical Trial Update: A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006) [Phase 2]

View source ↗

Summary

This document reports the results from a Phase 2a open-label safety and efficacy study of Tulisokibart (MK-7240/PRA023) in moderately to severely active Crohn's…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Tulisokibart

Snippet

Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Crohn Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-11-01